Dangerous New Cancer Tests Coming for Seniors?
There’s a new law on the books… and it could put American seniors everywhere in harm’s way.
It’s called H.R. 842 – and it clears the way for Medicare to start covering multi-cancer early detection (MCED) tests.
Sometimes known as “liquid biopsies” MCED tests claim they can use blood or other bodily fluids to catch 50+ types of cancer early.
So what could be wrong with that?
Plenty.
The tests could be outright dangerous for seniors – and the science behind them is so shoddy, that even America’s cancer doctors sounded the alarm.
But once Medicare starts covering MCED tests, they’re going to be pushed on seniors HARD.
So you need to act now to keep yourself safe.
Let’s get this straight from the horse’s mouth…
Four months before Congress passed a law authorizing Medicare to cover MCED tests, the official publication of the American Society of Clinical Oncology ran this headline:
Study Finds Insufficient Evidence Demonstrating Clinical Benefit of
Multicancer Detection Tests
Yep, you read that right. Our esteemed elected representatives passed this law blessing MCED tests after research called into question whether they should be used at all.
How’s that for “following the science?”
You see, in 2025, researchers conducted a thorough review on all of the research they could find on MCED tests, and pooled the results together. Again, I am going to give you direct quotes from what they found.
- “The evidence was limited; there were no completed randomized controlled trials.”
- “Diagnostic accuracy of currently available multi-cancer early detection tests varied substantially.”
- “Sensitivity was lower for detecting earlier-stage cancers (stages I-II) compared with later-stage cancers (stages III-IV).”
- No meaningful results were reported relating to patient-relevant outcomes, such as mortality, potential harms, health-related quality of life, acceptability or satisfaction.
So, basically, the researchers found that the science behind MCED tests didn’t meet even the simplest quality standards – and there was no evidence they were saving lives.
And the real kicker? These so-called “early detection” tests aren’t great at catching cancer early.
The real harm here is that countless patients… especially seniors… could end up getting aggressive treatments for cancers that are early, slow-growing, and may never threaten their lives.
Let’s be honest – once that MCED test comes back positive, patients are going to be scared and doctors are going to feel like they have to do something.
This happens every day already. Some health experts have argued that we have an epidemic of over-diagnosed and overtreated cancer in America – and these MCED tests are only going to make that worse.
There could come a time when MCED tests work well, are accurate, and can help save lives.
But everything about the science says they are not there yet – and could do more harm than good.
Our government didn’t listen to the facts. But now you have them for yourself.
To always telling you the truth,
Ray Thatcher
Research Director, Health Sciences Institute
Sources:
- ‘Epidemic of overdiagnosis and overtreatment’ prompts calls to redefine cancer. (2024, February 13). Healio. https://www.healio.com/news/hematology-oncology/20240213/epidemic-of-overdiagnosis-and-overtreatment-prompts-calls-to-redefine-cancer
- Levy, B., & Konety, B. (2026, January 28). Medicare may start covering multi-cancer early detection tests. It should proceed with caution. STAT. https://www.statnews.com/2026/01/28/multi-cancer-early-detection-tests-medicare-coverage/
- The ASCO Post. (2025, September 18). Study finds insufficient evidence demonstrating clinical benefit of multicancer detection tests. https://ascopost.com/news/september-2025/study-finds-insufficient-evidence-demonstrating-clinical-benefit-of-multicancer-detection-tests
- Wade R, Nevitt S, Liu Y, Harden M, Khouja C, Raine G, Churchill R, Dias S. Multi-cancer early detection tests for general population screening: a systematic literature review. Health Technol Assess. 2025 Jan;29(2):1-105. doi: 10.3310/DLMT1294. PMID: 39898371; PMCID: PMC11808444.


